Expression of TNF‐receptor associated factor 2 correlates with poor progression‐free survival time in ABC‐like primary nodal diffuse large B‐cell lymphomas
Expression of TNF‐receptor associated factor 2 correlates with poor progression‐free survival time in ABC‐like primary nodal diffuse large B‐cell lymphomas
复制标题
DOI：
10.1111/j.1365-2559.2008.02970.x
复制
发表时间：
2008-04
期刊：
影响因子：
6.4
通讯作者：
J. V. van Galen;J. Muris;C. Giroth;W. Vos;G. Ossenkoppele;C. Meijer;J. Oudejans
中科院分区：
文献类型：
--
作者：
J. V. van Galen;J. Muris;C. Giroth;W. Vos;G. Ossenkoppele;C. Meijer;J. Oudejans
目的：肿瘤坏死因子受体相关因子2(TRAF2)是一种参与核因子-κB活化的适配分子，是体外激活的B细胞样弥漫性大B细胞淋巴瘤的特征，可导致抗凋亡基因的表达和化疗的不良反应。TRAF2还通过干扰细胞凋亡信号转导通路，具有直接的抗细胞凋亡作用。目的是确定TRAF2是否在类似ABC的DLBCL中优先表达，以及表达是否与临床结果相关。
Aims: Tumour necrosis factor (TNF)‐receptor associated factor 2 (TRAF2) is an adaptor molecule involved in nuclear factor (NF)‐κB activation, which is characteristic of in vitro activated B‐cell (ABC)‐like diffuse large B‐cell lymphomas (DLBCL) and may result in expression of anti‐apoptotic genes and poor response to chemotherapy. TRAF2 also has direct anti‐apoptotic properties via interference with the apoptosis signalling cascade. The aim was to determine whether TRAF2 is preferentially expressed in ABC‐like DLBCL, and whether expression correlates with clinical outcome.